LEXICON PHARMACEUTICAL

Lexicon Announces Proposed Public Offering of Common Stock

31 May 2023 15:01:00 By Nasdaq GlobeNewswire

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

26 May 2023 15:05:00 By Nasdaq GlobeNewswire

New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

10 May 2023 15:30:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

02 May 2023 15:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023

28 Apr 2023 15:00:00 By Nasdaq GlobeNewswire

Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023

21 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference

17 Apr 2023 15:00:00 By Nasdaq GlobeNewswire

New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

04 Mar 2023 11:00:00 By Nasdaq GlobeNewswire

Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization

04 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update

02 Mar 2023 15:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023

28 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

20 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference

06 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

21 Dec 2022 15:29:56 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

14 Nov 2022 15:03:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference

11 Nov 2022 07:58:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update

09 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit

08 Nov 2022 07:58:00 By Nasdaq GlobeNewswire

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

06 Nov 2022 16:29:00 By Nasdaq GlobeNewswire